Geron Corporation GERN
0.97 USD -0.05 (-5.28%)
Nov 12, 2026, 2:54 PM EST
0.9613 Day range 1.02
0.84 52-week range 2.01
- YTD
- -26.81%
- 1 year
- -22.09%
News
marketbeat.com Geron Targets Germany Launch and Deals as RYTELO Sales Grow Geron NASDAQ: GERN is focusing on expanding U.S. use of its blood cancer drug RYTELO, preparing for a commercial sale in Germany and evaluating potential deals after discontinuing a late-stage trial…
defenseworld.net Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review Geron (NASDAQ: GERN - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
fool.com Geron: 3 Key Takeaways for Long-Term Investors RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.
benzinga.com Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six…
benzinga.com Geron Q3 2026 Earnings Call Transcript Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
benzinga.com Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
benzinga.com Geron Q2 2026 Earnings Call: Complete Transcript Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time…
benzinga.com Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MDS At EHA 2026 Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional…
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Geron Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 66.67 percent increase over losses of $(0.03) per…
benzinga.com Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Earnings Summary: Geron Q4 - benzinga.com Geron Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $48.015M Miss $50.420M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 47.06 percent. This is a 25 percent decrease over losses of $(0.04) per…
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Top 2 Tech Stocks That May Fall Off A Cliff This Quarter 
benzinga.com Top 2 Industrials Stocks That Are Ticking Portfolio Bombs 
benzinga.com Top 3 Health Care Stocks That May Collapse This Quarter 
benzinga.com Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks - benzinga.com Geron Implements Strategic Restructuring, Cutting Workforce By One-Third And Incurring ~$18M In Charges On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic restructuring plan intended to position the Company for long-term value creation for patients and…
benzinga.com Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - benzinga.com Geron Showcases New ASH 2025 Data Highlighting RYTELO's Durable Efficacy And Survival Trends Across LR-MDS And Myelofibrosis Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including…
benzinga.com Geron Expects 2025 Operating Expenses Will Be Between $250M And $260M vs. Approximately $270M-$285M Prior 2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be between $250 million and $260 million, compared to previously announced guidance of approximately…
benzinga.com Earnings Scheduled For November 5, 2025 
benzinga.com Geron Earnings Preview - benzinga.com Geron To Present New RYTELO Data On LR-MDS And Myelofibrosis At ASH 2025 New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDSAdditional poster…
- benzinga.com Geron's COO Andrew Grethlein To Depart On October 15, 2025 FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Geron Q2 EPS $(0.02) Beats $(0.03) Estimate, Sales $49.036M Beat $47.281M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 80 percent increase over losses of $(0.10) per…
- benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com Goldman Sachs Reinstates Sell on Geron, Announces $1 Price Target Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1 price target.- benzinga.com Goldman Sachs Initiates Coverage On Geron with Sell Rating, Announces Price Target of $1 Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell rating and announces Price Target of $1.
benzinga.com Geron Highlights New IMerge Post-Hoc Analyses Demonstrating RYTELO's Clinical Benefit In Lower-Risk MDS Patients Across Key Subgroups, Alongside Quality-of-Life And Transfusion Independence Data At ASCO And EHA 2025 New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Geron Q1 EPS $(0.03) Beats $(0.04) Estimate, Sales $39.60M Miss $48.22M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 66.67 percent increase over losses of $(0.09) per…
- benzinga.com Earnings Scheduled For May 7, 2025
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com Scotiabank Maintains Sector Outperform on Geron, Lowers Price Target to $4 Scotiabank analyst Greg Harrison maintains Geron (NASDAQ:GERN) with a Sector Outperform and lowers the price target from $6 to $4.
- benzinga.com Stifel Maintains Buy on Geron, Lowers Price Target to $4 Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $8 to $4.
- benzinga.com Barclays Maintains Overweight on Geron, Lowers Price Target to $4 Barclays analyst Peter Lawson maintains Geron (NASDAQ:GERN) with a Overweight and lowers the price target from $9 to $4.
benzinga.com Needham Maintains Buy on Geron, Lowers Price Target to $5 Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $7 to $5.
benzinga.com Dow Dips Over 100 Points; TJX Earnings Top Views 
benzinga.com Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings - benzinga.com Geron Q4 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $47.54M Beat $45.66M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 55.56 percent increase over losses of $(0.09) per…
- benzinga.com Earnings Scheduled For February 26, 2025
- benzinga.com 4 Analysts Assess Geron: What You Need To Know
- benzinga.com B. Riley Securities Maintains Buy on Geron, Lowers Price Target to $3.5 B. Riley Securities analyst Kalpit Patel maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $5.5 to $3.5.